Gooderham M, Papp K. Clinical Trial and Registry Data. Curr Probl Dermatol 2018; 53: 15-27. Epub 2017 Nov 7. PMID: 29131034 / doi: 10.1159/000478074

Blauvelt A, Gooderham M, Iversen L, Ball S, Zhang L, Agada NO, Reich K. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol 2017 Nov; 77(5): 855-62. Epub 2017 Sep 13. PMID: 28917383 / doi: 10.1016/j.jaad.2017.06.153

Gooderham M, McDonald J, Papp K. Diagnosis and Management of Conjunctivitis for the Dermatologist. J Cutan Med Surg 2017 Nov 1: 1203475417743233 [Epub ahead of print]. PMID: 29191053 / doi: 10.1177/1203475417743233

Mayba JN, Gooderham MJ. A Guide to Topical Vehicle Formulations. J Cutan Med Surg 2017 Nov 1: 1203475417743234 [Epub ahead of print]. PMID: 29137492 / doi: 10.1177/1203475417743234

Vu TT, Gooderham M. Adverse Drug Reactions and Cutaneous Manifestations Associated With Anticoagulation. J Cutan Med Surg 2017 Nov/Dec; 21(6): 540-50. Epub 2017 Jun 22. PMID: 28639463 / doi: 10.1177/1203475417716364

Alavi A, Lynde C, Alhusayen R, Bourcier M, Delorme I, George R, Gooderham M, Gulliver W, Kalia S, Marcoux D, Poulin Y. Approach to the Management of Patients With Hidradenitis Suppurativa: A Consensus Document. J Cutan Med Surg 2017 Nov/Dec; 21(6): 513-24. Epub 2017 Jun 22. PMID: 28639459 / doi: 10.1177/1203475417716117

Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol 2017 Oct 25 [Epub ahead of print]. PMID: 29102053 / doi: 10.1016/j.jaad.2017.08.051

Bissonnette R, Haydey R, Rosoph LA, Lynde CW, Bukhalo M, Fowler JF, Delorme I, Gagné-Henley A, Gooderham M, Poulin Y, Barber K, Jenkin P, Landells I, Pariser DM. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study. J Eur Acad Dermatol Venereol 2017 Oct 21 [Epub ahead of print]. PMID: 29055155 / doi: 10.1111/jdv.14647

Lebwohl MG, Papp KA, Marangell LB, Koo J, Blauvelt A, Gooderham M, Wu JJ, Rastogi S, Harris S, Pillai R, Israel RJ. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. J Am Acad Dermatol 2017 Oct 3 [Epub ahead of print]. PMID: 28985956 / doi: 10.1016/j.jaad.2017.08.024

Lynde CW, Bourcier M, Gooderham M, Guenther L, Hong CH, Papp KA, Poulin Y, Sussman G, Vender R. A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults. J Cutan Med Surg 2017 Oct 1: 1203475417733460 [Epub ahead of print]. PMID: 29082775 / doi: 10.1177/1203475417733460

Verma L, Mayba JN, Gooderham MJ, Verma A, Papp KA. Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices. J Cutan Med Surg 2017 Oct 1: 1203475417733957 [Epub ahead of print]. PMID: 29056080 / doi: 10.1177/1203475417733957

Mehdizadeh A, Alavi A, Alhusayen R, Bauer B, Bechara FG, Bourcier M, Brassard A, Djamei V, Dutz J, George R, Ghias M, Gooderham M, Hamzavi I, Hoffman LK, Hou A, Hu H, Kimball AB, Kirchhof M, Kryzskaya D, Liy Wong MDC, Lowes MA, Lynde CW, McLellen C, Prens E, Prens L, Rogalska T, Sibbald RG, Sisic M, Tan MG, Wong DD. Proceeding report of the Symposium on Hidradenitis Suppurativa Advances (SHSA). Exp Dermatol 2017 Sep 12 [Epub ahead of print]. PMID: 28898476 / doi: 10.1111/exd.13445

Bissonnette R, Bourcier M, Gooderham M, Hong CH, Landells I, Lynde C, Papp K, Poulin Y, Vender R, Wiseman MC. Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. J Cutan Med Surg 2017 Sep/Oct; 21(2_suppl): 2S-40S. PMID: 29156950 / doi: 10.1177/1203475417722552

Gold LS, Papp K, Lynde C, Lain E, Gooderham M, Johnson S, Kerrouche N. Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% Gel: A randomized, vehicle-controlled study. J Drugs Dermatol 2017 Sep 1; 16(9): 909-16. PMID: 28915286

Leonardi CL, Blauvelt A, Sofen HL, Gooderham M, Augustin M, Burge R, Zhu B, Reich K. Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: Results from UNCOVER-2 and UNCOVER-3. J Eur Acad Dermatol Venereol 2017 Sep; 31(9): 1483-90. Epub 2017 Jun 28. PMID: 28294430 / doi: 10.1111/jdv.14211

Lima H, Gooderham M, Dutz J, Lynde C, Chapdelaine H, Ellis A, Gilbert M, Ho V, Papp K, Poulin Y, Sussman G. Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome. Allergy Asthma Clin Immunol 2017 Aug 24; 13: 38. PMID: 28852410 / doi: 10.1186/s13223-017-0210-0

Papp KA, Gooderham MJ, Girard G, Raman M, Strout V. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol 2017 Aug; 31(8): 1324-32. Epub 2017 Jun 14. PMID: 28556418 / doi: 10.1111/jdv.14313

Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomised, double-blind, 52-week, phase 3 study in moderate-to-severe plaque psoriasis patients. Br J Dermatol 2017 Jul 28 [Epub ahead of print]. PMID: 28755394 / doi: 10.1111/bjd.15857

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017 Jun 10; 389(10086): 2287-303. Epub 2017 May 4. PMID: 28478972 / doi: 10.1016/S0140-6736(17)31191-1

Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Narbutt J, Philipp S, Spelman L, Weglowska J, Zhang N, Strober B. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol 2017 Jun; 76(6): 1093-102. Epub 2017 Mar 11. PMID: 28291552 / doi: 10.1016/j.jaad.2016.12.014

Papp K, Albrecht L, Barber K, Bourcier M, Dion P-L, Freiman A, Gooderham M, Guenther L, Gulliver W, Hong C, Lynde C, Poulin Y, Siddha S, Toole J, Toth D, Vender R, Wasel N, Wiseman M. An open letter to Health Canada. J Cutan Med Surg 2017; 21(3): 195-6. doi: 10.1177/1203475417704642

Nicholas MN, Gooderham MJ. Atopic dermatitis, depression, and suicidality. J Cutan Med Surg 2017 May/Jun; 21(3): 237-42. Epub 2017 Jan 9. PMID: 28300443 / doi: 10.1177/1203475416685078

Nicholas MN, Gooderham M. Psoriasis, Depression, and Suicidality. Skin Therapy Lett 2017 May; 22(3): 1-4. PMID: 28486717

Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, Menter A, Philipp S, Sofen H, Tyring S, Berner BR, Visvanathan S, Pamulapati C, Bennett N, Flack M, Scholl P, Padula SJ. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med 2017 Apr 20; 376(16): 1551-60. PMID: 28423301 / doi: 10.1056/NEJMoa1607017

Gladman DD, Poulin Y, Adams K, Bourcier M, Barac S, Barber K, Chandran V, Dutz J, Flanagan C, Gooderham MJ, Gulliver WP, Ho VC, Hong C, Karsh J, Khraishi MM, Lynde CW, Papp KA, Rahman P, Rohekar S, Rosen CF, Russel AS, Vender RB, Yeung J, Ziouzina O, Zummer M. Treating psoriasis and psoriatic arthritis: Position paper on applying the treat-to-target concept to Canadian daily practice. J Rheumatol 2017; 44(4): 519-34.

Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J, Shah K, Piguet V, Soung J. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol 2017 Mar; 31(3): 507-17. Epub 2016 Dec 19. PMID: 27768242 / doi: 10.1111/jdv.14015

Mayba JN, Gooderham MJ. Real-World Experience With Apremilast in Treating Psoriasis. J Cutan Med Surg 2017 Mar/Apr; 21(2): 145-51. Epub 2016 Oct 23. PMID: 27846617 / doi: 10.1177/1203475416676030

Gooderham M, Lynde CW, Papp K, Bourcier M, Guenther L, Gulliver W, Hong CH, Poulin Y, Sussman G, Vender R. Review of systemic treatment options for adult atopic dermatitis. J Cutan Med Surg 2017 Jan/Feb; 21(1): 31-9. Epub 2016 Sep 22. PMID: 27635033 / doi: 10.1177/1203475416670364

Pickard AS, Gooderham M, Hartz DS, Nicolay C. EQ-5D health utilities: Exploring ways to improve upon responsiveness in psoriasis. J Med Econ 2017 Jan; 20(1): 19-27. PMID: 27471948

Feldman SR, Thaci D, Gooderham M, Augustin M, de la Cruz C, Mallbris L, Buonanno M, Tatulych S, Kaur M, Lan S, Valdez H, Mamolo C. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 2016 Dec; 75(6): 1162-70.e3. PMID: 27692733 / doi: 10.1016/jaad.2016.07.040

Gooderham M, Bourcier M, de Gannes G, Dhadwal G, Fahim S, Gulliver W, Landells I, Lynde , Metelitsa A, Nigen S, Poulin Y, Pratt M, Shear NH, Siddha S, Taher Z, Vender R. Management of Chronic Hand Dermatitis: A Practical Guideline for the General Practitioner. Skin Therapy Letter - Family Practice Edition 2016; 11(1)

Alavi A, Adam DN, Alhusayan R, Boucier M, Brassard A, Coutts P, Gooderham M, Gulliver W, Hong CH, Lynde C, Marcoux D, Papp K, Poulin Y, Sibbald RG, Shear NH. Definition of Moderate to Severe Hidradenitis Suppurativa: A Position Paper by the Canadian Hidradenitis Suppurativa Foundation (CHSF). J Cutan Med Surg 2016 Nov; 20(6): 613-15. PMID: 27821541

Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, Wang C, Purohit V, Mamolo C, Papacharalambous J, Ports WC. Topical tofacitinib for atopic dermatitis: A Phase 2a randomised trial. Br J Dermatol 2016 Nov; 175(5): 902-11. Epub 2016 Jul 16. PMID: 27423107 / doi: 10.1111/bjd.14871

Vu H TT, Gooderham M, Papp K. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis. Expert Rev Clin Pharmacol 2016 Nov; 9(11): 1423-33. Epub 2016 Oct 11. PMID: 27690669 / doi: 10.1080/17512433.2016.1242409

Mayba J, Gooderham M. Treatment of palmoplantar pustulosis with the combination of ustekinumab and apremilast: A case report. Arc Cas Rep CMed 2016 Oct 13; 2(3): 128.

Papp KA, Bissonnette R, Gooderham M, Feldman SR, Iversen L, Soung J, Draelos Z, Mamolo C, Purohit V, Wang C, Ports WC. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial. BMC Dermatol 2016 Oct 3; 16(1): 15. PMID: 27715172

Gooderham M, Gavino-Velasco J, Clifford C, MacPherson A, Krasnoshtein F, Papp K. A review of psoriasis, therapies, and suicide. J Cutan Med Surg 2016 Jul; 20(4): 293-303. Epub 2016 May 5. PMID: 27207348 / doi: 10.1177/1203475416648323

Menter A, Papp KA, Gooderham M, Pariser DM, Augustin M, Kerdel FA, Fakharzadeh S, Goyal K, Calabro S, Langholff W, Chavers S, Naessens D, Sermon J, Krueger GG. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol 2016 Jul; 30(7): 1148-58. Epub 2016 Mar 30. PMID: 27027388 / doi: 10.1111/jdv.13611

Blakely K, Gooderham M, Papp K. Dupilumab, a monoclonal antibody for atopic dermatitis: a review of current literature. Skin Therapy Letter 2016 Mar-Apr; 21(2): 1-5.

Blakely K, Gooderham M. Management of scalp psoriasis: current perspectives. Psoriasis: Targets and Therapy 2016 Mar 29; 6: 33-40.

Gooderham MJ, Poulin-Costello M, Shelton J, Bayan N, Papp KA. Predictors of topical use in psoriasis patients in the REFINE study. J Cutan Med Surg 2016 Mar; 20(2): 106-12. Epub 2015 Sep 1. PMID: 26330052 / doi: 10.1177/1203475415604322

Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, Crowley J. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol 2016 Jan; 74(1): 134-42. PMID: 26549249 / doi: 10.1016/j.jaad.2015.09.001

Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015 Dec; 173(6): 1387-99. Epub 2015 Nov 7. PMID: 26357944 / doi: 10.1111/bjd.14164

Gooderham M, Papp K. The psychosocial impact of hidradenitis suppurativa. J Am Acad Dermatol 2015 Nov; 73(5 Suppl 1): S19-22. PMID: 26470609 / doi: 10.1016/j.jaad.2015.07.054

Gooderham M, Papp K. Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast. BioDrugs 2015 Oct; 29(5): 327-39. PMID: 26481941

Gooderham M, Papp K. Apremilast in the treatment of psoriasis and psoriatic arthritis. Skin Therapy Lett 2015 Sep-Oct; 20(5): 1-6. PMID: 26382906

Hartleib MC, Gooderham M. Top ten things rheumatologists should (and might not) know about inflammation and CV disease. CRAJ 2015 Fall; 25(3).

Ham K, Posso-De Los Rios CJ, Gooderham M. Methylisothiazolinone testing at 2000 ppm: a prevalent sensitizer for allergic contact dermatitis. Dermatitis 2015 Jul-Aug; 26(4): 166-9. PMID: 26172485 / doi: 10.1097/DER.0000000000000121

Gooderham M, Posso-De Los Rios CJ, Rubio-Gomez GA, Papp K. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review. Skin Therapy Lett 2015 Jan-Feb; 20(1): 1-5. PMID: 25807214

Gooderham M, Debarre JM, Keddy-Grant J, Xu Z, Kurvits M, Goodfield M. Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12-17 years of age. Br J Dermatol 2014 Dec; 171(6): 1470-7. Epub 2014 Oct 22. PMID: 24980277 / doi: 10.1111/bjd.13235

Tan J, Humphrey S, Vender R, Barankin B, Gooderham M, Kerrouche N, Audibert F, Lynde C; POWER study group. A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin. Br J Dermatol 2014 Dec; 171(6): 1508-16. Epub 2014 Oct 28. PMID: 24934963 / doi: 10.1111/bjd.13191

Ham K, Maini P, Gooderham MJ. Real-world experience with alitretinoin in a community dermatology practice setting in patients with chronic hand dermatitis. J Cutan Med Surg 2014 Sep-Oct; 18(5): 332-6. PMID: 25186994

Gooderham M. Small molecules: an overview of emerging therapeutic options in the treatment of psoriasis. Skin Therapy Lett 2013 Dec; 18(7): 1-4. PMID: 24305752

Fallen RS, Gooderham M. Rosacea: Update on management and emerging therapies. Skin Therapy Lett 2012 Nov-Dec; 17(10): 1-4. PMID: 23223767

Fallen RS, Gooderham M. Ingenol mebutate: An introduction. Skin Therapy Lett 2012 Feb; 17(2): 1-3. PMID: 22358305

Katipunan K, Gooderham M. Topical management of psoriasis and the role of vitamin D3 analogues. Skin Therapy Letter – Family Practice Edition 2011 Sep; 7(4).

Fallen RS, Gooderham M. Bedbugs: An update on recognition and management. Skin Therapy Lett 2011 Jun; 16(6): 5-7. PMID: 21833462

Davidson M, Gooderham M. Review of management options for genital herpes infections. Skin Therapy Letter – Family Practice Edition 2011 Feb; 7(1).

Gooderham M. A review of therapeutic options for genital warts. Skin Therapy Letter – Family Practice Edition 2009 Jun; 5(2): 1-4.

Gooderham M. A review of therapeutic options for genital warts. Skin Therapy Letter – Pharmacist Edition 2009 May-Jun; 4(1): 4-7.

Gooderham M. Rosacea and its topical management. Skin Therapy Lett 2009 Feb; 14(2): 1-3. PMID: 19330270

Gooderham M, Solish N. Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy. Dermatol Surg 2005 Jan; 31(1): 104-108. PMID: 15720106 

Gooderham MJ, Solish N. Diminished buccal fat. J Am Acad Dermatol 2004; 50(5): 804.

Gooderham MJ, DeKoven J. Crusted erosions on the back and intertriginous areas. J Am Acad Dermatol 2003; 48(5): 801-802.

Gooderham MJ, Shaw JC. Pruritic eruption in an elderly man. J Am Acad Dermatol 2003; 48(5): 802-803.

Gooderham MJ. Traumatic injury by a cat. J Am Acad Dermatol 2002; 47(5): 803-804.

Gooderham MJ. Newborn with fusion of the eyelids. J Am Acad Dermatol 2002; 47(5): 804.

Gooderham MJ, Bolli P, Fernandez PG. Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin.  Ann Pharmacother 1999 Jul-Aug; 33(7-8): 796-799. PMID: 10466907

Gooderham MJ, Guenther L. Sun and the skin: evaluation of a sun awareness program for elementary school students. J Cutan Med Surg 1999 Jul; 3(5): 230-235. PMID: 10381945

Gooderham MJ, Guenther L. Impact of a sun awareness curriculum on medical students’ knowledge, attitudes, and behaviour. J Cutan Med Surg 1999 Apr; 3(4): 182-187. PMID: 10366391

Gooderham MJ, Adlercreutz H, Ojala ST, Wähälä K, Holub BJ. A soy protein isolate rich in genistein and daidzein and its effects on plasma isoflavone concentrations, platelet aggregation, blood lipids and fatty acid composition of plasma phospholipid in normal men. J Nutr 1996 Aug; 126(8): 2000-2006. PMID: 8759372